The Fund seeks to track the investment results of the ICE Biotechnology Index, which measures the performance of US-listed securities of companies that are classified within the Biotechnology Sub-Industry Group. The Fund generally invests at least 90% of its assets in securities of the Underlying Index.
| Classification | Inception Date | Primary Exchange |
|---|---|---|
| Health/Biotech Funds | 02/05/2001 | Nasdaq |
Investment Information
| Market Cap | 9.12B |
| Net Assets | 8.75B |
| NAV | 136.75 |
| Shares Outstanding | 66.50M |
| Avg Daily Vol | 1.62M |
| Dividend Yield | 0.30% |
| Dividend | 0.10 |
| Ex Dividend Date | 12/13/22 |
Detailed Information
| Mgmt Co | BlackRock |
| Turnover | 46.00% |
| Beta | 0.65 |
| P/E | 25.80 |
| P/B | 9.27 |
| Expense Ratio | 0.44% |
To receive a prospectus
BlackRock4400 Computer Drive
Westborough, MA 01581
800-474-2737
Performance
| IBB | S&P 500 TR IX | |
|---|---|---|
| 1 week | 1.11 | 2.24 |
| 4 weeks | 6.48 | 6.27 |
| 3 months | 8.05 | 5.31 |
| 1 year | 7.64 | -6.27 |
| 3 years | 5.67 | 8.55 |
| 5 years | 3.46 | 9.09 |
| 10 years | 11.08 | 12.48 |
